Nexell's Baxter deal leaves it without future
This article was originally published in Clinica
Executive Summary
Lengthy and unsuccessful efforts to raise capital was one of the key reasons behind Nexell's decision last week to opt for closure. Staff posts will be cut to just three while the Irvine, California company progresses with an orderly wind down. Efforts to merge the company with a third party also proved fruitless. Finally, Nexell opted for the chosen course in order to preserve its assets and meet its obligations, said president and CEO William Albright.
You may also be interested in...
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.